印度的制药部门正在转向高价值产品,促进了出口和创新。 India's pharma sector is shifting to high-value products, boosting exports and innovation.

根据《2025-26年经济调查》,印度制药业正在从数量转向价值,侧重于复杂的非专利物、生物类同物和创新。 India’s pharmaceutical industry is shifting from volume to value, focusing on complex generics, biosimilars, and innovation, according to the 2025-26 Economic Survey. 它供应了20%的全球非专利商品,向191个国家出口,在25财政年度赚取了4.72亿卢比,每年出口增长7%。 It supplies 20% of global generics, exports to 191 countries, and earned ₹4.72 lakh crore in FY25, with exports growing at 7% annually. 超过一半流向美国和欧洲等受监管市场, 印度拥有3%的股份, Over half go to regulated markets like the US and Europe, where India holds a 3% share and ranks 11th by value. 医疗设备出口从21财政年度的25亿美元增加到41亿美元,生产了诸如MRI扫描仪和通风机等先进设备。 Medical device exports rose to $4.1 billion from $2.5 billion in FY21, with production of advanced equipment like MRI scanners and ventilators. 印度仍然是负担得起的疫苗的最大供应商。 India remains a top supplier of affordable vaccines. 该部门正在通过研发、AI、3D印刷和简化全球认证来提高竞争力而向前推进。 The sector is advancing through R&D, AI, 3D printing, and simplified global certifications to boost competitiveness.